 CytoDyn Inc OTCQB:CYDY has shared strong preliminary results from its Phase 1b2 trials and compassionate use study of its flagship drug candidate leronlimab in 30 metastatic triple-negative breast cancer mTNBC patients. The leronlimab trial is being carried out in combination with carboplatin for the treatment of metastatic triple-negative breast cancer. 